ELMD · Electromed, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELMD
this stock
Electromed, Inc.
|
$230.15M | -7.0% | +13.8% | 21.2 | 2.3% |
|
ABT
Abbott Laboratories
|
$183.29B | -16.0% | +5.7% | 29.5 | 1.2% |
|
MDT
Medtronic plc
|
$118.41B | -4.3% | +8.4% | 22.8 | 1.1% |
|
SYK
Stryker Corp
|
$105.63B | -21.6% | +11.2% | 28.5 | 1.8% |
|
BSX
Boston Scientific Corp
|
$64.14B | -52.8% | +12.5% | 17.9 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELMD | -0.1% | -36.1% | +16.8% | -3.2% | -7.0% |
| SPY | +0.1% | -1.1% | +15.3% | -0.6% | +11.8% |
| vs SPY | -0.2% | -35.1% | +1.6% | -2.6% | -18.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.